Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers.

Clinical pharmacokinetics - 1 Jan 2004

Kirchheiner Julia, Meineke Ingolf, Müller Göran, Bauer Steffen, Rohde Wolfgang, Meisel Christian, Roots Ivar, Brockmöller Jürgen

Abstract excerpt

BACKGROUND: The oral hypoglycaemic drug nateglinide is eliminated from the human body via hepatic biotransformation and renal tubular secretion. According to in vitro data, about 70% of nateglinide intrinsic clearance may be mediated by cytochrome P450 (CYP) 2C9 and a smaller fraction by CYP3A4 and CYP2D6. OBJECTIVE: To assess the impact of CYP2C9 polymorphisms and of the CYP2D6 poor metaboliser genotype on the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aryl Hydrocarbon Hydroxylases
Share to Cyclohexanes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C9

Share to Cytochrome P-450 CYP2D6

Share to Glucagon

Share to Hypoglycemic Agents

Share to Metabolic Clearance Rate

Share to Phenylalanine

Source

Identifiers

PMID: 15005635
DOI: 10.2165/00003088-200443040-00005

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers.PMID 15005635Read ↗

Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers.Semantic proximity Read ↗

Effect of CYP2C9 and SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of nateglinide in healthy Chinese male volunteers.Semantic proximity Read ↗

CYP2C metabolism of oral antidiabetic drugs--impact on pharmacokinetics, drug interactions and pharmacogenetic aspects.Semantic proximity Read ↗

Influence of CYP2C19 genotype on the pharmacokinetics of R483, a CYP2C19 substrate, in healthy subjects and type 2 diabetes patients.Semantic proximity Read ↗

In vitro assessment of 36 CYP2C9 allelic isoforms found in the Chinese population on the metabolism of glimepiride.Semantic proximity Read ↗

Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype.Semantic proximity Read ↗

NAT2 phenotype alters pharmacokinetics of rivaroxaban in healthy volunteers.Semantic proximity Read ↗

Influence of CYP2C9 gene polymorphisms on response to glibenclamide in type 2 diabetes mellitus patients.Semantic proximity Read ↗

Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes.Semantic proximity Read ↗

Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjects.Semantic proximity Read ↗

The presence of two reduced function variants in CYP2C9 influences the acute response to glipizide.Semantic proximity Read ↗

Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.